188 related articles for article (PubMed ID: 22635030)
1. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.
Grisham RN; Adaniel C; Hyman DM; Ma W; Iasonos A; Aghajanian C; Konner J
Int J Gynecol Cancer; 2012 Jun; 22(5):807-11. PubMed ID: 22635030
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
3. Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
Suprasert P; Cheewakriangkrai C; Manopunya M
Asian Pac J Cancer Prev; 2012; 13(2):517-20. PubMed ID: 22524817
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T
Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151
[TBL] [Abstract][Full Text] [Related]
5. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K
Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Grisham RN; Iyer G; Sala E; Zhou Q; Iasonos A; DeLair D; Hyman DM; Aghajanian C
Int J Gynecol Cancer; 2014 Jul; 24(6):1010-4. PubMed ID: 24978709
[TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ
Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695
[TBL] [Abstract][Full Text] [Related]
8. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
9. Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy.
Ezewuiro O; Grushko TA; Kocherginsky M; Habis M; Hurteau JA; Mills KA; Hunn J; Olopade OI; Fleming GF; Romero IL
PLoS One; 2016; 11(1):e0147145. PubMed ID: 26788855
[TBL] [Abstract][Full Text] [Related]
10. Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
Vandenput I; Vergote I; Neven P; Amant F
Int J Gynecol Cancer; 2012 May; 22(4):617-22. PubMed ID: 22426408
[TBL] [Abstract][Full Text] [Related]
11. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
[TBL] [Abstract][Full Text] [Related]
12. Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.
Safra T; Ron I; Boaz M; Brenner J; Grisaru D; Inbar M; Hayat H; Menczer J; Golan A; Levy T
Acta Oncol; 2006; 45(4):463-8. PubMed ID: 16760183
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
Sufliarsky J; Chovanec J; Svetlovska D; Minarik T; Packan T; Kroslakova D; Lalabova R; Helpianska L; Horvathova D; Sevcik L; Spacek J; Laluha A; Tkacova V; Malec V; Rakicka G; Magdin D; Jancokova I; Dorr A; Stresko M; Habetinek V; Koza I
Neoplasma; 2009; 56(4):291-7. PubMed ID: 19473054
[TBL] [Abstract][Full Text] [Related]
14. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer.
Yuan SF; Zhang LP; Zhu LJ; Chen WJ; Zheng WE; Xiong JP
Asian Pac J Cancer Prev; 2013; 14(6):3949-53. PubMed ID: 23886213
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
Gallego A; Ramon-Patino J; Brenes J; Mendiola M; Berjon A; Casado G; Castelo B; Espinosa E; Hernandez A; Hardisson D; Feliu J; Redondo A
Clin Transl Oncol; 2021 Mar; 23(3):536-542. PubMed ID: 32651885
[TBL] [Abstract][Full Text] [Related]
17. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
Zhao D; Wu LY; Wang XB; Li XG
Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
[TBL] [Abstract][Full Text] [Related]
18. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?
Rocconi RP; Sullivan P; Long B; Blaize M; Brown J; Arbuckle J; Bevis K; Estes JM; Reed E; Finan MA
Int J Gynecol Cancer; 2012 Jun; 22(5):786-91. PubMed ID: 22552832
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Li Y; Yang Y; Shang YM; Zheng H
Indian J Cancer; 2014 Mar; 51 Suppl 3():e92-4. PubMed ID: 25818742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
